Alternative za pretraživanje:
rheumato venereologist » dermato venereologica (Proširi pretraživanje), dermato venereologie (Proširi pretraživanje)
dermato venerology » dermato venereology (Proširi pretraživanje), dermato venereologie (Proširi pretraživanje), _ dermatovenerology (Proširi pretraživanje)
dermatol venereol » dermato venereology (Proširi pretraživanje), dermato venereologie (Proširi pretraživanje)
eur acad » nur acar (Proširi pretraživanje), eur ace (Proširi pretraživanje)
j eur » j eum (Proširi pretraživanje), _ eur (Proširi pretraživanje), j ebr (Proširi pretraživanje)
Prikaz rezultata 61 – 80 od 492 za pretraživanje 'j eur acad ((dermatol venereol) OR (((dermato venerology) OR (rheumato venereologist))))', vrijeme pretraživanja: 1,51s Detaljiziraj rezultate
Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

SARS‐CoV‐2 spike protein is present in both endothelial and eccrine cells of a chilblain‐like skin lesion
Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders

Depression and the risk of psoriasis in US women
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

A patient‐centred approach to biological treatment decision making for psoriasis: an expert consensus
Public primary and secondary skin cancer prevention, perceptions and knowledge: an international cross‐sectional survey

Symmetric chest pressure ulcers, consequence of prone position ventilation in a patient with COVID‐19
Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

Absence of SARS‐CoV‐2 RNA detection in tissue samples of COVID‐19‐related cutaneous lesions analyzed by real‐time RT‐PCR
Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

A novel missense variant in the PNPLA1 gene underlies congenital ichthyosis in three consanguineous families
Antiviral gene expression in psoriasis

Host risk factors for the development of multiple non-melanoma skin cancers
Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study

Burden of chronic urticaria relative to psoriasis in five European countries
Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments

Alati za pretraživanje: Preuzmi RSS sažetak — Pošalji ovo pretraživanje e-poštom — Spremi pretraživanje